KEY POINTS
- REQUITE prospectively enrolled 2,057 women receiving adjuvant external-beam breast radiotherapy after breast-conserving surgery across 27 centers in seven countries. CTCAE toxicity and patient-reported outcomes were collected longitudinally, with follow-up extending to eight years at participating centers.
- Among 2,056 patients with fractionation data, 1,062 received ≤2.2 Gy per fraction and 994 received >2.2 Gy per fraction. The typical breast prescription was 50 Gy in 25 fractions in the lower-dose-per-fraction group and approximately 40 Gy in 15 fractions in the hypofractionated group.
- Acute skin toxicity peaked at treatment completion. Erythema of any grade occurred in 89% after normofractionation versus 83% after hypofractionation; grade 2 erythema occurred in 29% versus 16%, and grade 3 erythema in 2.3% versus 0.4%, respectively.
- Clinically significant acute pain was also less frequent with hypofractionation: grade ≥2 pain occurred in 11% versus 4.3% at the end of RT. Grade ≥2 skin ulceration was approximately 4.8% versus 0.8%, driven predominantly by the conventionally fractionated group.
- Late toxicity was generally low grade. Skin induration was the most frequently reported late effect, reaching 8.6% grade ≥2 at one year in the normofractionated group and 7.8% at four years in the hypofractionated group; grade 3 events across late endpoints were rare.
- Breast atrophy was already present before RT in 5.4% and 3.4% of the two fractionation groups, illustrating the difficulty of separating surgical from radiation effects. The highest observed grade ≥2 atrophy rates were 10.5% at two years after normofractionation and 16.8% at three years after hypofractionation.
- Patient-reported breast symptoms increased during treatment but returned toward baseline thereafter. Median global quality-of-life score was 67 before RT and 83 among respondents at 5–8 years, but long-term interpretation is limited by attrition: CTCAE data were available for only 48% at ≥5 years, and questionnaire response fell to 1.7% by year 8.
CLINICAL TAKEAWAY
REQUITE provides large prospective real-world confirmation that contemporary breast hypofractionation is associated with less acute skin toxicity and pain than older normofractionated schedules, while severe late effects remain uncommon. Because treatment schedules differed strongly by country, boost use, technique, and other clinical factors, these descriptive data complement rather than replace randomized trial evidence.